3-chloro-3-phenyl-5-methoxy-1-(3H)-isobenzofuranone | 92261-05-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 英文名称: 3-chloro-3-phenyl-5-methoxy-1-(3H)-isobenzofuranone
• 英文别名: 3-Chloro-5-methoxy-3-phenyl-2-benzofuran-1-one
• CAS: 92261-05-7
• 化学式: C₁₅H₁₁ClO₃
• 分子量: 274.704
• InChiKey: AXQXJMBFCNDYJB-UHFFFAOYSA-N

物化性质

• 沸点：
  454.2±45.0 °C(Predicted)
• 密度：
  1.36±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-chloro-3-phenyl-5-methoxy-1-(3H)-isobenzofuranone 在 2,6-二甲基吡啶 、 四氧化锇 、 N-甲基吗啉氧化物 作用下， 以 水 、 丙酮 、 甲苯 为溶剂， 生成 2-[(2R)-2,3-dihydroxypropyl]-6-methoxy-1-oxo-4-phenyl-1,2-dihydroisoquinoline-3-carbonitrile
  参考文献：
  名称：

  Design and Synthesis of Novel Isoquinoline-3-nitriles as Orally Bioavailable Kv1.5 Antagonists for the Treatment of Atrial Fibrillation

  摘要：

  Novel 3-cyanoisoquinoline Kv1.5 antagonists have been prepared and evaluated in in vitro and in vivo assays for inhibition of the Kv1.5 potassium channel and its associated cardiac potassium current, I-Kur. Structural modifications of isoquinolinone lead 1 afforded compounds with excellent potency, selectivity, and oral bioavailability.

  DOI：

  10.1021/jm060927v
• 作为产物：
  描述：

  4-甲氧基-N-甲基苯甲酰胺 在 盐酸 、 正丁基锂 、 氯化亚砜 、 四甲基乙二胺 、 溶剂黄146 、 N,N-二甲基甲酰胺 作用下， 以 四氢呋喃 、 1,2-二氯乙烷 为溶剂， 生成 3-chloro-3-phenyl-5-methoxy-1-(3H)-isobenzofuranone
  参考文献：
  名称：

  Design and Synthesis of Novel Isoquinoline-3-nitriles as Orally Bioavailable Kv1.5 Antagonists for the Treatment of Atrial Fibrillation

  摘要：

  Novel 3-cyanoisoquinoline Kv1.5 antagonists have been prepared and evaluated in in vitro and in vivo assays for inhibition of the Kv1.5 potassium channel and its associated cardiac potassium current, I-Kur. Structural modifications of isoquinolinone lead 1 afforded compounds with excellent potency, selectivity, and oral bioavailability.

  DOI：

  10.1021/jm060927v

文献信息

• Sulfonylurea compounds and their use in treating diabetes
  申请人：ADIR, S.A.R.L.

  公开号：US04505921A1

  公开（公告）日：1985-03-19

  New sulfonylurea compounds of the formula: ##STR1## in which n is 1 or 2, R is thienyl, furyl, pyridyl or phenyl optionally mono or disubstituted, R.sub.1 and R.sub.2, the same or different, each are hydrogen, halogen, (C.sub.1 to C.sub.5)-alkyl, (C.sub.1 to C.sub.5)-alkoxy, or trifluoromethyl, or together represent --CH.sub.2 --O--CH.sub.2 --, R.sub.3 is hydrogen, or hydroxy, and R.sub.4 is (C.sub.1 to C.sub.5)-alkyl, (C.sub.3 to C.sub.8)-cycloalkyl or azacycloalkyl of the formula: ##STR2## in which p is zero or an integer from 1 to 5, or azabicycloalkyl of the formula: ##STR3## in which m is 1, 2, or 3. These new compounds and physiologically tolerable salts thereof may be used as medicines especially in the treatment of diabetes.

  新的磺酰脲化合物的化学式为：##STR1## 其中n为1或2，R为噻吩基、呋喃基、吡啶基或苯基，可选择性地为单取代或双取代，R.sub.1和R.sub.2，相同或不同，分别为氢、卤素、(C.sub.1到C.sub.5)-烷基、(C.sub.1到C.sub.5)-烷氧基或三氟甲基，或者一起表示--CH.sub.2 --O--CH.sub.2 --，R.sub.3为氢或羟基，R.sub.4为(C.sub.1到C.sub.5)-烷基、(C.sub.3到C.sub.8)-环烷基或化学式为：##STR2## 其中p为零或1到5的整数，或者化学式为：##STR3## 其中m为1、2或3。这些新化合物及其生理耐受盐可用作药物，特别用于糖尿病的治疗。
• Methods and compositions for the treatment of neurodegenerative disorders
  申请人：Jin Xiaowei

  公开号：US20080044390A1

  公开（公告）日：2008-02-21

  The present invention features compositions, kits, and methods for treating, preventing, and ameliorating neurodegenerative disorders, e.g., Huntington's disease.
• US4505921A
  申请人：——

  公开号：US4505921A

  公开（公告）日：1985-03-19
• [EN] METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS<br/>[FR] MÉTHODES ET COMPOSITIONS POUR LE TRAITEMENT DE TROUBLES NEURODÉGÉNÉRATIFS
  申请人：COMBINATORX INC

  公开号：WO2008021210A2

  公开（公告）日：2008-02-21

  [EN] The present invention features compositions, kits, and methods for treating, preventing, and ameliorating neurodegenerative disorders, e.g., Huntington's disease.
  [FR] La présente invention comporte des compositions, des kits et des méthodes pour traiter, prévenir et guérir des troubles neurodégénératifs, par exemple, la maladie de Huntington.
• Design and Synthesis of Novel Isoquinoline-3-nitriles as Orally Bioavailable Kv1.5 Antagonists for the Treatment of Atrial Fibrillation
  作者：B. Wesley Trotter、Kausik K. Nanda、Nathan R. Kett、Christopher P. Regan、Joseph J. Lynch、Gary L. Stump、Laszlo Kiss、Jixin Wang、Robert H. Spencer、Stefanie A. Kane、Rebecca B. White、Rena Zhang、Kenneth D. Anderson、Nigel J. Liverton、Charles J. McIntyre、Douglas C. Beshore、George D. Hartman、Christopher J. Dinsmore

  DOI：10.1021/jm060927v

  日期：2006.11.30

  Novel 3-cyanoisoquinoline Kv1.5 antagonists have been prepared and evaluated in in vitro and in vivo assays for inhibition of the Kv1.5 potassium channel and its associated cardiac potassium current, I-Kur. Structural modifications of isoquinolinone lead 1 afforded compounds with excellent potency, selectivity, and oral bioavailability.